Collegium Pharmaceutical (COLL) Intangibles (2018 - 2026)

Collegium Pharmaceutical's Intangibles history runs 7 years deep, the most recent figure standing at $614.0 million for Q1 2026.

• On a quarterly basis, Intangibles fell 26.54% year-over-year to $614.0 million in Q1 2026; TTM through Mar 2026 was $614.0 million, a 26.54% decrease from a year earlier, with the FY2025 full-year figure at $669.5 million, down 24.89% from the prior year.
• Intangibles slipped to $614.0 million in Q1 2026 per COLL's latest filing, from $669.5 million in the prior quarter.
• Across five years, Intangibles topped out at $966.2 million in Q1 2022 and bottomed at $352.7 million in Q2 2024.
• The 5-year median for Intangibles is $725.0 million (2025), against an average of $704.2 million.
• Across the five-year window, Intangibles tumbled 59.29% in 2024 and surged 121.3% in 2025, its largest moves.
• Year by year, Intangibles stood at $567.5 million in 2022, then retreated by 25.69% to $421.7 million in 2023, then surged by 111.38% to $891.4 million in 2024, then dropped by 24.89% to $669.5 million in 2025, then dropped by 8.29% to $614.0 million in 2026.
• Per Business Quant, the three latest COLL Intangibles figures stand at $614.0 million (Q1 2026), $669.5 million (Q4 2025), and $725.0 million (Q3 2025).